Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients

• Published in: Postępy w kardiologii interwencyjnej 2020-12, Vol.16 (4), p.391-398
• Main Authors: Cakal, Beytullah, Cakal, Sinem, Karaca, Oguz, Omaygenc, Mehmet Onur, Yilmaz, Filiz Kizilirmak, Gunes, Haci Murat, Ozcan, Ozgur Ulas, Yıldırım, Arzu, Boztosun, Bilal
• Format: Article
• Language: English
• Subjects: bioresorbable scaffolds; Cardiology; Cardiovascular disease; Clinical outcomes; coronary artery disease; Coronary vessels; Original Paper; percutaneous coronary intervention; Stents; Thrombosis; Tissue engineering
• ISSN: 1734-9338; 1897-4295
• DOI: 10.5114/aic.2020.101763

Elevated risk of adverse events in comparison to metallic stents resulted in withdrawal of everolimus-eluting bioresorbable scaffolds (eBVS), known as the most intensively studied BVS. There is a paucity of data comparing the two different BVS. To evaluate the long-term clinical outcomes of the novolimus-eluting bioresorbable vascular scaffold (nBVS) compared with eBVS. Consecutive patients treated with nBVS or eBVS in our center were screened. The primary outcome was the 3-year rate of major adverse cardiovascular events (MACE), defined as the composite of cardiac death, target vessel myocardial infarction (TV-MI), and target-lesion revascularization (TLR). After matching, 98 patients treated with 135 eBVS were compared with 98 patients treated with 136 nBVS. Baseline characteristics, clinical presentation, and lesion characteristics were comparable in both groups. The 3-year MACE rate was higher in the eBVS group (17.3% vs. 6.1%; log-rank = 0.02). The occurrence of TLR (16.3% vs. 5.1%; log-rank = 0.02) and TV-MI (8.2% vs. 0 %; log-rank = 0.004) was also higher in the eBVS group except for cardiac deaths (1% vs. 2%; log-rank = 0.98, eBVS vs. nBVS, respectively). Of note, definite device thrombosis rate was markedly increased in the eBVS group (5.1% vs. 0%; log-rank = 0.03). The present study revealed that the 3-year event risk was lower for nBVS compared to eBVS. More evidence is needed to evaluate long-term performance of novolimus-eluting biovascular platforms.